In the context of anti-PD-1 therapy in cancer treatment, the ratio of Ki-67+ cells among PD-1+CD8+ T cells after treatment compared with baseline is predictive of long-term treatment outcomes [17]. This evidence concerns the gene MKI67 and cancer.